NRSN Stock Overview
A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
NeuroSense Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.52 |
| 52 Week High | US$1.63 |
| 52 Week Low | US$0.51 |
| Beta | 1.34 |
| 1 Month Change | 54.01% |
| 3 Month Change | 39.45% |
| 1 Year Change | 30.25% |
| 3 Year Change | 2.01% |
| 5 Year Change | n/a |
| Change since IPO | -62.38% |
Recent News & Updates
Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22Shareholder Returns
| NRSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.2% | 1.0% | -2.7% |
| 1Y | 30.2% | -13.2% | 9.0% |
Return vs Industry: NRSN exceeded the US Biotechs industry which returned -13% over the past year.
Return vs Market: NRSN exceeded the US Market which returned 10.5% over the past year.
Price Volatility
| NRSN volatility | |
|---|---|
| NRSN Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NRSN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NRSN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 17 | Alon Ben-Noon | www.neurosense-tx.com |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease.
NeuroSense Therapeutics Ltd. Fundamentals Summary
| NRSN fundamental statistics | |
|---|---|
| Market cap | US$35.02m |
| Earnings (TTM) | -US$10.21m |
| Revenue (TTM) | n/a |
Is NRSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRSN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.21m |
| Earnings | -US$10.21m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NRSN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 10:34 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroSense Therapeutics Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Jason Kolbert | D. Boral Capital LLC. |
| Nazibur Rahman | Maxim Group |